Insys Litigation Documents – Annotated Bibliography

In addition to documents in the Archive, the following sources may be useful in understanding the context of the Insys litigation.

Select Background Regarding General Opioid Litigation

- Minhee, C. (2021). Opioid Settlement Tracker. Tracks opioid-related litigation to determine whether settlements are being used to support public health efforts. Includes FAQs, timelines, and analysis.

Select Background Focused on Insys Therapeutics, Inc.

- Insys Therapeutics. (2013). About Us. Preserves archived version of Insys Therapeutics website, with descriptions of products, leadership team, Board of Directors, and compliance practices.

- Epiq. (2019). Insys Therapeutics, Inc. Outlines Insys bankruptcy case background, important information and dates, parties, and debtors.

- United States Department of Justice. (2019, June 5). Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations. Justice News. Announces the resolution of the Department of Justice’s investigations into Insys, summarizing the company’s counts of fraud and violations as well as executive convictions. Details Insys’s forfeiture and fines, as well as the company’s agreements for deferred prosecution and a Corporate Integrity Agreement.

- Emanuel, G. and Thomas, K. (2019, May 2) Top Executives of Insys, an Opioid Company, Are Found Guilty of Racketeering. New York Times. Summarizes the 10-week federal trial and situates the trial and charges in the context of individuals, not just pharmaceutical companies, being held accountable for their roles in the opioid crisis.

Description of “Great by Choice” rap video, shown at the 2019 racketeering conspiracy trial of Insys executives, which featured company sales representatives as well as Vice President of Sales Alec Burlakoff.


  Gives the history of Insys’s promotion of Subsys from the investor perspective. Covers Insys’s responses to investment firms after indictments and arrests of physicians, and how those firms parroted the messaging to their clients. Draws attention to the role of the Sunshine Act in physician indictments.


  Covers in depth the history of Insys Therapeutics, the company’s illegal practices, and the history of investigations into, and litigation against, the company. This exposé was expanded into *The Hard Sell*, published in 2022.


  Report 2 (2018 Feb.) - *Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups*
